Medpace Holdings, Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 18.0% margin the price requires 16.4% 3y revenue CAGR against 9.3% consensus, a cushion of -16.9pt versus a 3pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. The best customer channel in the batch: biotech funding feeds bookings.
Would recover if: biotech funding tightens and book-to-bill drops back toward 0.88x. We re-check this against analyst estimates every evening.
10 years, at a 18% margin analysts expect
+6.5%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
10 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 147% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 12, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the 40th percentile of published models, broadly endorsing the middle of the analyst set and fully paying for a growth deceleration from 20% down to roughly 8% annually.
Can the Q2 2026 rebound in bookings to a 1.13x book-to-bill ratio be sustained, or will cancellations return to drag the ratio back toward the 0.88x low seen just one quarter earlier? The available data can measure the resulting revenue volumes by segment, but cannot directly measure the underlying cancellation rates or RFP trends.
What the price refuses to pay for, and the full reconstruction, on the MEDP quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names